E214: Beyond Copilot

What this episode covers

For many life sciences teams, the first wave of AI has looked like copilots: smart search, quick answers, and help on demand. Useful, but passive. In this episode, Dr Andree Bates is joined by Parth Khanna, CEO and co-founder of ACTO, to explore what comes next: moving beyond copilots into role-based AI agents that proactively close knowledge gaps, improve field readiness, and operate safely inside regulated environments.Parth shares his path into life sciences and tech, including founding an early NLP company in 2012 and then building ACTO after speaking with over 100 life science companies about field force effectiveness. Today, ACTO supports tens of thousands of professionals and hundreds of brand launches, and Parth argues the industry is now entering the “agentic era” where the real differentiator is not just model access, but how organisations build context, control, and change management around AI.A key theme is why generic AI tools often fail inside enterprises. Parth outlines four requirements for agent success: context (role and job-specific personalisation), connection (stitching data sources and agent-to-agent workflows), control (testing, monitoring, observability), and change management (reducing fear and driving adoption). Without these, he says, many copilots and assistants end up underused, with people quietly reverting to old workflows.Parth then introduces ACTO’s concept of role-based “super agents”, designed around a real job description (for example an MSL). Rather than a disconnected swarm of task bots, a “queen bee” orchestrator agent delegates to worker agents, checks outputs against compliance guardrails, and can be assessed with exams to quantify risk before deployment. This approach, he argues, makes AI both more powerful and safer for regulated field teams.Finally, the conversation looks ahead. Parth believes the future of work depends on pairing AI capability with distinctly human strengths: strategy, judgement, and human connection. The winners won’t be those who automate the most tasks, but those who redesign roles so humans and agents amplify each other.Topics CoveredWhy copilots are useful but fundamentally passiveThe shift from AI that responds to AI that actsWhy generic tools fail: context, connection, control, change managementAdoption reality: why many AI assistants go unusedQuantifying risk and moving from black box to observable AIRole-based super agents and the “queen bee” orchestrator modelTesting agents with exams before field deploymentGuardrails, compliance, and agent-to-agent quality checksHuman skills AI can’t replace: strategy, judgement, connectionThe future of MSL and field excellence in an agentic eraEularis helps pharma and biotech leaders turn AI activity into board-defensible strategy and measurable commercial outcomes.If your organisation has plenty of AI in motion but very little that moves the commercial needle in a way the board can see, start with our 10-Day AI Diagnostic Sprint. It’s a focused diagnostic that surfaces what’s actually broken and what’s blocking results, before you invest in a larger strategy effort.The Sprint diagnoses the problem. The AI Strategic Blueprint that follows is where we build the board-defensible strategy and plan.Details at eularis.com.About the PodcastAI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.

PodParley-generated summary based on available episode metadata and transcript content.